Display Settings:

Format

Send to:

Choose Destination
    Prostate Cancer Prostatic Dis. 2009;12(4):355-60. Epub 2009 May 26.

    First-year costs of treating prostate cancer: estimates from SEER-Medicare data.

    Source

    Department of Urology, UT Southwestern Medical Center at Dallas, Dallas, TX, USA.

    Abstract

    Pharmacologic therapies are currently being evaluated for the prevention of prostate cancer (PCa). As additional clinical data become available regarding their benefits and risks, an examination of their economic impact will also be important. The purpose of this study was to estimate mean per patient PCa-related costs during the first year following diagnosis and to examine the extent to which initial therapies are used, by initial cancer stage. Our data show that health-care costs were significant and varied by stage. With average first-year PCa-related costs of US$13,091, prevention strategies have the potential to reduce health-care costs.

    PMID:
    19468284
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Nature Publishing Group

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk